Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michèle Cavo, Jesús F. San Miguel, Saad Z. Usmani, Katja Weisel, Meletios A Dimopoulos, Hervé Avet‐Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vânia Hungria, Philippe Moreau, María‐Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Façon, Shaji Kumar, Niels W.C.J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil C. Munshi (2021). Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. , 139(6), DOI: https://doi.org/10.1182/blood.2021011101.
Article18 days agoSustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva, Shaji Kumar, Meletios A Dimopoulos, Thierry Façon, María‐Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michèle Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis (2021). Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. , 139(4), DOI: https://doi.org/10.1182/blood.2020010439.
Article18 days agoA large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi, Hervé Avet‐Loiseau, Kenneth C. Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios A Dimopoulos, Margarita Kulakova, Annette Lam, Mahmoud Hashim, Jianming He, Bart Heeg, Jon Ukropec, Jessica Vermeulen, Sarah Côté, Nizar J. Bahlis (2020). A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. , 4(23), DOI: https://doi.org/10.1182/bloodadvances.2020002827.
Article18 days agoDaratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Jonathan L. Kaufman, Meletios A Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Heather J. Sutherland, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Sonali Trivedi, Tineke Casneuf, Maria Krevvata, Jon Ukropec, Rachel Kobos, Hervé Avet‐Loiseau, Saad Z. Usmani, Jesús F. San Miguel (2020). Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. , 10(11), DOI: https://doi.org/10.1038/s41408-020-00375-2.
Article18 days agoSustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone
Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva, Shaji Kumar, Meletios A Dimopoulos, Thierry Façon, María‐Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michèle Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis (2020). Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone. , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-134928.
Article18 days ago